[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors]

Abstract

The effectiveness and tolerability of xeloda (capecitabine), a tumor-reactivated oral fluoropyrimidine, alone were investigated in 19 patients, aged 39-79, with relapsing and cisplatin-resistant ovarian tumors. Unfavorable prognosis of chemotherapy was in 11 cases (57.8%): cisplatin-resistant tumors (7) and early relapse--before month 6 (4). Xeloda was administered orally, 1,250 mg/m2, twice a day, for two weeks at an interval of one week. A total of 68 cycles (an average of 3.6 cycles) were evaluated. Complete response was registered in 1, partial--4, and stabilization--4 cases. Total response was in 26.3%, clinically significant effect--47.3% (9 out of 19). Toxic side-effects generally persisted with in stage I-II (palm-and-sole syndrome, leukopenia, neutropenia, sickness, vomiting, diarrhea) without interfering with the treatment.